menorrhagia.
Conditions
Interventions
Tranksymyk acid 250 mg capsule three times a day (every 8 hours) Mefenamic acid 250 mg capsule three times a day (every 8 hours).
Treatment - Drugs
Tranksymyk acid 250 mg capsule three times a day (every 8 hours) Mefenamic acid 250 mg capsule three times a day (every 8 hours)
Sponsors
Vice chancellor for research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: willingness to cooperate in women using TCU380 (IUD); no experiment coagulation disorders and systemic disorders; none ultrasound malignancies; counting padding to verify menorrhagia; none use of other methods of contraception; no disease of the digestive and liver, brain and kidney; no trombosis; no history of allergy to mefenamic acid and hemoglobin; no history thrombosis and clotting disorders; no history of irregular uterine bleeding; uterine size between 9-6 cm; hemoglobin above 10; having 1 to 5 parity and no unwanted pregnancy. Exclusion criteria: sensitivity to the drug use the drug note continued; dissatisfaction with the plan; unwanted pregnancy with IUD and IUD removal.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menorrhagia. Timepoint: before intervention and first and second months after intervention. Method of measurement: PBAC Table. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: One month and two months after intervention. Method of measurement: Standard questionnaire. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed